Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EBIT (2016 - 2025)

Historic EBIT for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to $12.9 million.

  • Ascendis Pharma A's EBIT rose 11210.04% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $409.1 billion, marking a year-over-year increase of 11954021.06%. This contributed to the annual value of -$301.7 million for FY2024, which is 3844.23% up from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's EBIT is $12.9 million, which was up 11210.04% from -$59.9 million recorded in Q2 2025.
  • Ascendis Pharma A's EBIT's 5-year high stood at $409.3 billion during Q4 2024, with a 5-year trough of -$154.2 million in Q1 2023.
  • In the last 5 years, Ascendis Pharma A's EBIT had a median value of -$141.7 million in 2021 and averaged $21.4 billion.
  • In the last 5 years, Ascendis Pharma A's EBIT soared by 103912092.86% in 2024 and then crashed by 10532.03% in 2025.
  • Over the past 5 years, Ascendis Pharma A's EBIT (Quarter) stood at -$128.8 million in 2021, then decreased by 16.76% to -$150.4 million in 2022, then skyrocketed by 73.8% to -$39.4 million in 2023, then surged by 1039120.93% to $409.3 billion in 2024, then crashed by 100.0% to $12.9 million in 2025.
  • Its EBIT stands at $12.9 million for Q3 2025, versus -$59.9 million for Q2 2025 and -$109.6 million for Q1 2025.